A Study of Benralizumab in Patients with Eosinophilic Esophagitis - MESSINA

Study identifier:D3255C00001

ClinicalTrials.gov identifier:NCT04543409

EudraCT identifier:2019-002871-32

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis

Medical condition

Eosinophilic Esophagitis

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

211

Study type

Interventional

Age

12 Years - 65 Years

Date

Study Start Date: 22 Sept 2020
Primary Completion Date: 19 Sept 2022
Study Completion Date: 06 Feb 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria